Clinical Trial Update: Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of ranibizumab and bromfenac for neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• BROMFENAC (Bromfenac)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Oregon Health and Science University | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED